# CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA

> **NCT07558434** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 43 (estimated)

## Conditions studied

- Severe Aplastic Anemia (SAA)
- Transfusion-dependent Non-severe Aplastic Anemia

## Interventions

- **DRUG:** Cyclosporine (CsA)
- **DRUG:** thrombopoietin receptor agonist (TPO-RA)
- **DRUG:** Romiplostim N01

## Key facts

- **NCT ID:** NCT07558434
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07558434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07558434, "CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07558434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*